Novavax Corporate Overview & Investor Deck May 2021

Novavax presents its corporate overview and investor deck highlighting nanoparticle vaccine development capabilities and COVID-19 clinical trial progress. The company demonstrates 96% efficacy against the original COVID-19 strain with 50,000+ trial participants and projected manufacturing capacity of 150 million doses monthly by Q4 2021.